Key Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences & Research Unit of Peptide Science, Chinese Academy of Medical Sciences, 2019RU066, Lanzhou University, Lanzhou 730000, China.
Key Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences & Research Unit of Peptide Science, Chinese Academy of Medical Sciences, 2019RU066, Lanzhou University, Lanzhou 730000, China; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
Biochem Pharmacol. 2024 Jul;225:116269. doi: 10.1016/j.bcp.2024.116269. Epub 2024 May 7.
Antimicrobial peptides (AMPs), which have a low probability of developing resistance, are considered the most promising antimicrobial agents for combating antibiotic resistance. Feleucin-K3 is an amphiphilic cationic AMP that exhibits broad-spectrum antimicrobial activity. In our previous research, the first phenylalanine residue was identified as the critical position affecting its biological activity. Here, a series of Feleucin-K3 analogs containing hydrophobic D-amino acids were developed, leveraging the low sensitivity of proteases to unnatural amino acids and the regulatory effect of hydrophobicity on antimicrobial activity. Among them, K-1dF, which replaced the phenylalanine of Feleucin-K3 with its enantiomer (D-phenylalanine), exhibited potent antimicrobial activity with a therapeutic index of 46.97 and MICs between 4 to 8 μg/ml against both sensitive and multidrug-resistant Acinetobacter baumannii. The introduction of D-phenylalanine increased the salt tolerance and serum stability of Feleucin-K3. Moreover, K-1dF displayed a rapid bactericidal effect, a low propensity to develop resistance, and a synergistic effect when combined with antibiotics. More importantly, it exhibited considerable or superior efficacy to imipenem against pneumonia and skin abscess infection. In brief, the K-1dF obtained by simple and effective modification strategy has emerged as a promising candidate antimicrobial agent for tackling multidrug-resistant Acinetobacter baumannii infections.
抗菌肽(AMPs)被认为是最有前途的对抗抗生素耐药性的抗菌药物之一,因为它们产生耐药性的可能性较低。Feleucin-K3 是一种两亲性阳离子 AMP,具有广谱抗菌活性。在我们之前的研究中,第一个苯丙氨酸残基被确定为影响其生物活性的关键位置。在这里,开发了一系列含有疏水性 D-氨基酸的 Feleucin-K3 类似物,利用蛋白酶对非天然氨基酸的低敏感性和疏水性对抗菌活性的调节作用。其中,用 Feleucin-K3 的对映体(D-苯丙氨酸)取代苯丙氨酸的 K-1dF 表现出强大的抗菌活性,治疗指数为 46.97,对敏感和多药耐药鲍曼不动杆菌的 MIC 值在 4 至 8μg/ml 之间。D-苯丙氨酸的引入提高了 Feleucin-K3 的耐盐性和血清稳定性。此外,K-1dF 表现出快速杀菌作用、低耐药倾向和与抗生素联合使用时的协同作用。更重要的是,它对肺炎和皮肤脓肿感染的疗效与亚胺培南相当或优于亚胺培南。总之,通过简单有效的修饰策略获得的 K-1dF 已成为一种有前途的治疗多重耐药鲍曼不动杆菌感染的候选抗菌药物。